An improved d-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance

Journal of Controlled Release

Volumn 196, Issue , 2014, Pages 272-286

  Lu, Jianqin ^a,b   Zhao, Wenchen ^a   Liu, Hao ^c   Marquez, Rebecca ^c   Huang, Yixian ^a,b   Zhang, Yifei ^a,b   Li, Jiang ^a,b   Xie, Wen ^a,b   Venkataramanan, Raman ^a   Xu, Liang ^c   Li, Song ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

Chemotherapeutics; Drug interactive motif; Fluorenylmethyloxycarbonyl; Nanomedicine; Reversal of multidrug resistance

Indexed keywords

CHEMOTHERAPEUTICS; DOXORUBICIN; DRUG-INTERACTIVE MOTIF; FLUORENYLMETHYLOXYCARBONYL; IMPROVED D; MULTIDRUG RESISTANCE; NANOCARRIERS; TARGETED DELIVERY;

MEDICAL NANOTECHNOLOGY;

ADENOSINE TRIPHOSPHATASE; ALPHA TOCOPHEROL; DOXORUBICIN; DRUG CARRIER; NANOCARRIER; ANTINEOPLASTIC ANTIBIOTIC; NANOMATERIAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CIRCULATION; CYTOTOXICITY ASSAY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; FEMALE; HUMAN; HUMAN CELL; MALE; MAXIMUM TOLERATED DOSE; MICELLE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROSTATE CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; NUDE MOUSE; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATASES; ALPHA-TOCOPHEROL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; NANOSTRUCTURES; TISSUE DISTRIBUTION;

EID: 84908404335     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.10.016     Document Type: Article

References (51)

1. O. Tacar, P. Sriamornsak, and C.R. Dass Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems J. Pharm. Pharmacol. 65 2013 157 170
2. F.A. Fornari, J.K. Randolph, J.C. Yalowich, M.K. Ritke, and D.A. Gewirtz Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells Mol. Pharmacol. 45 1994 649 656
3. R.L. Momparler, M. Karon, S.E. Siegel, and F. Avila Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells Cancer Res. 36 1976 2891 2895
4. Y. Pommier, E. Leo, H. Zhang, and C. Marchand DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem. Biol. 17 2010 421 433
5. G. Takemura, and H. Fujiwara Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management Prog. Cardiovasc. Dis. 49 2007 330 352
6. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 56 2004 185 229
7. Y. Mi, Y. Liu, and S.S. Feng Formulation of docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS2k) micelles for targeted and synergistic chemotherapy Biomaterials 32 2011 4058 4066
8. K.Y. Win, and S.S. Feng In vitro and in vivo studies on vitamin E TPGS-emulsified poly(d, l-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation Biomaterials 27 2006 2285 2291
9. Y. Ma, Y. Zheng, K. Liu, G. Tian, Y. Tian, and L. Xu Nanoparticles of poly(lactide-co-glycolide)-d-α-tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment Nanoscale Res. Lett. 6 2010 1161 1169
10. J. Wang, J. Sun, Q. Chen, Y. Gao, L. Li, and H. Li Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance Biomaterials 28 2012 6877 6888
11. M.S. Muthu, S.A. Kulkarni, J. Xiong, and S.S. Feng Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells Int. J. Pharm. 421 2011 332 340
12. N. Cao, and S.S. Feng Doxorubicin conjugated to d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation Biomaterials 29 2008 3856 3865
13. V. Anbharasi, N. Cao, and S.S. Feng Doxorubicin conjugated to d-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy J. Biomed. Mater. Res. A 94 2010 730 743
14. L. Yu, A. Bridgers, J. Polli, A. Vickers, S. Long, and A. Roy Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability Pharm. Res. 16 1999 1812 1817
15. J.M. Dintaman, and J.A. Silverman Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) Pharm. Res. 16 1999 1550 1556
16. M.V.S. Varma, and R. Panchagnula Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo Eur. J. Pharm. Sci. 25 2005 445 453
17. E.M. Collnot, C. Baldes, U.F. Schaefer, K.J. Edgar, M.F. Wempe, and C.M. Lehr Vitamin E TPGS p-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access Mol. Pharm. 7 2010 642 651
18. P.P. Constantinides, J.H. Han, and S.S. Davis Advances in the use of tocols as drug delivery vehicles Pharm. Res. 23 2006 243 255
19. Y. Huang, J. Lu, X. Gao, J. Li, W. Zhao, and M. Sun PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel Bioconjug. Chem. 23 2012 1443 1451
20. J. Lu, Y. Huang, W. Zhao, R.T. Marquez, X. Meng, and J. Li PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers Biomaterials 34 2013 1591 1600
21. X. Zhang, J. Lu, Y. Huang, W. Zhao, Y. Chen, and J. Li PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel Bioconjug. Chem. 24 2013 464 472
22. Y. Chen, X. Zhang, J. Lu, Y. Huang, J. Li, and S. Li Targeted delivery of curcumin to tumors via PEG-derivatized FTS-based micellar system AAPS J. 16 2014 600 608
23. J.Y. Kim, S. Kim, M. Papp, K. Park, and R. Pinal Hydrotropic solubilization of poorly water-soluble drugs J. Pharm. Sci. 99 2010 3953 3965
24. J.Y. Kim, S. Kim, R. Pinal, and K. Park Hydrotropic polymer micelles as versatile vehicles for delivery of poorly water-soluble drugs J. Control. Release 152 2011 13 20
25. X. Gao, Y. Huang, A.M. Makhov, M. Epperly, J. Lu, and S. Grab Nanoassembly of surfactants with interfacial drug-interactive motifs as tailor-designed drug carriers Mol. Pharm. 10 2013 187 198
26. P. Zhang, J. Lu, Y. Huang, W. Zhao, Y. Zhang, and X. Zhang Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier AAPS J. 16 2014 114 124
27. J. Lu, Y. Huang, W. Zhao, Y. Chen, J. Li, and X. Gao Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel Mol. Pharm. 10 2013 2880 2890
28. Y. Zhang, H. Gu, Z. Yang, and B. Xu Supramolecular hydrogels respond to ligand-receptor interaction J. Am. Chem. Soc. 125 2003 13680 13681
29. V. Jayawarna, M. Ali, T.A. Jowitt, A.F. Miller, A. Saiani, and J.E. Gough Nanostructured hydrogels for three-dimensional cell culture through self-assembly of fluorenylmethoxycarbonyl-dipeptides Adv. Mater. 18 2006 611 614
30. A. Mahler, M. Reches, M. Rechter, S. Cohen, and E. Gazit Rigid, self-assembled hydrogel composed of a modified aromatic dipeptide Adv. Mater. 18 2006 1365 1370
31. Y. Wang, R. Wang, X. Lu, W. Lu, C. Zhang, and W. Liang Pegylated phospholipids-based self-assembly with water-soluble drugs Pharm. Res. 27 2010 361 370
32. J. Mao, H. Zhang, J. Luo, L. Li, R. Zhao, R. Zhang, and G. Liu New method for HPLC separation and fluorescence detection of malonaldehyde in normal human plasma J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 832 2006 103 108
33. Y. Zhao, D.Y. Alakhova, J.O. Kim, T.K. Bronich, and A.V. Kabanov A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer J. Control. Release 168 2013 61 69
34. C.M. Hu, and L. Zhang Therapeutic nanoparticles to combat cancer drug resistance Curr. Drug Metab. 10 2009 836 841
35. M.M. Gottesman Mechanisms of cancer drug resistance Annu. Rev. Med. 53 2002 615 627
36. H. Yuan, X. Li, J. Wu, J. Li, X. Qu, and W. Xu Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance Curr. Med. Chem. 15 2008 470 476
37. M. Tijerina, K.D. Fowers, P. Kopecková, and J. Kopecek Chronic exposure of human ovarian carcinoma cells to free or HPMA copolymer-bound mesochlorin e6 does not induce P-glycoprotein-mediated multidrug resistance Biomaterials 21 2000 2203 2210
38. P.V. Desai, G.A. Sawada, I.A. Watson, and T.J. Raub Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux Mol. Pharm. 10 2013 1249 1261
39. D. Xu, H. Kang, M. Fisher, and R.L. Juliano Strategies for inhibition of MDR1 gene expression Mol. Pharmacol. 66 2004 268 275
40. K. Ogawara, K. Un, K. Tanaka, K. Higaki, and T. Kimura In vivo anti-tumour effect of PEG liposomal doxorubicin (DOX) in DOX resistant tumour-bearing mice: involvement of cytotoxic effect on vascular endothelial cells J. Control. Release 133 2009 4 10
41. J. Luo, K. Xiao, Y. Li, J.S. Lee, L. Shi, and Y.H. Tan Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment Bioconjug. Chem. 21 2010 1216 1224
42. Y. Li, K. Xiao, J. Luo, J. Lee, S. Pan, and K.S. Lam A novel size-tunable nanocarrier system for targeted anticancer drug delivery J. Control. Release 144 2010 314 323
43. K. Xiao, J. Luo, Y. Li, J.S. Lee, G. Fung, and K.S. Lam PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma J. Control. Release 155 2011 272 281
44. A. Shirpoor, L. Norouzi, M.H. Khadem Ansari, B. Ilkhanizadeh, and R. Gharaaghaji Vasoprotective effect of vitamin E: rescue of ethanol-induced atherosclerosis and inflammatory stress in rat vascular wall Int. Immunopharmacol. 16 2013 498 504
45. J. Buse, and A. El-Aneed Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances Nanomedicine (London) 5 2010 1237 1260
46. C.T. Yen, T.L. Hwang, Y.C. Wu, and P.W. Hsieh Design and synthesis of new N-(fluorenyl-9-methoxycarbonyl) (Fmoc)-dipeptides as anti-inflammatory agents Eur. J. Med. Chem. 44 2009 1933 1940
47. X. Chen, X. Wang, Y. Wang, L. Yang, J. Hu, and W. Xiao Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide J. Control. Release 145 2010 17 25
48. T. Ishida, E. Shiraga, and H. Kiwada Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model J. Control. Release 134 2009 194 200
49. R.M. Schiffelers, G.A. Koning, T.L. ten Hagen, M.H. Fens, A.J. Schraa, and A.P. Janssen Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin J. Control. Release 91 2003 115 122
50. J.H. Maeng, D.H. Lee, K.H. Jung, Y.H. Bae, I.S. Park, and S. Jeong Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer Biomaterials 31 2010 4995 5006
51. Y. Ma, D. Liu, D. Wang, Y. Wang, Q. Fu, J.K. Fallon, X. Yang, Z. He, and F. Liu Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer Mol. Pharm. 11 2014 2623 2630